T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

May 2018 | 48 pages | ID: T9A629B607CEN
Global Markets Direct

Abstracts

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2018'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

The report 'T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2018' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Encephalomyelitis, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Sepsis, Skin And Soft Tissue Infections, Solid Tumor, Stem Cell Transplantation, Systemic Lupus Erythematosus and Uveitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
• The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
• The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
Atox Bio Ltd
Five Prime Therapeutics Inc
Johnson & Johnson
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
ALPN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALPN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CD278 and CD28 and Antagonize PD-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections
Sep 20, 2017: Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model
May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology
Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections
Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Atox Bio Ltd, H1 2018
Pipeline by Five Prime Therapeutics Inc, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by TheraMAB LLC, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Atox Bio Ltd
Five Prime Therapeutics Inc
Johnson & Johnson
TheraMAB LLC